{'52WeekChange': 0.49404764,
 'SandP52WeekChange': 0.0644362,
 'address1': '65 Grove Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.69,
 'askSize': 1300,
 'averageDailyVolume10Day': 1102762,
 'averageVolume': 2376285,
 'averageVolume10days': 1102762,
 'beta': 1.394172,
 'beta3Year': None,
 'bid': 2.48,
 'bidSize': 3000,
 'bookValue': -0.101,
 'category': None,
 'circulatingSupply': None,
 'city': 'Watertown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 2.59,
 'dayLow': 2.47,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.994,
 'enterpriseToRevenue': 26.358,
 'enterpriseValue': 175726096,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617-924-3454',
 'fiftyDayAverage': 2.8887143,
 'fiftyTwoWeekHigh': 4.83,
 'fiftyTwoWeekLow': 1.28,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 63015318,
 'forwardEps': -0.48,
 'forwardPE': -5.229167,
 'fromCurrency': None,
 'fullTimeEmployees': 39,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.17365,
 'heldPercentInstitutions': 0.60208,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/selectabio.com',
 'longBusinessSummary': 'Selecta Biosciences, Inc., a clinical-stage '
                        'biopharmaceutical company, researches and develops '
                        'nanoparticle immunomodulatory drugs for the treatment '
                        'and prevention of human diseases. Its proprietary '
                        'pipeline includes therapeutic enzymes, gene '
                        'therapies, and other products and product candidates '
                        "affected by undesired immune responses. The company's "
                        'lead product is SEL-212 that in Phase II clinical '
                        'trials for the treatment of chronic refractory gout. '
                        'It is also developing SEL-403, which is in Phase I '
                        'clinical trials for the treatment of patients with '
                        'malignant pleural or peritoneal mesothelioma. In '
                        'addition, the company engages in the development of '
                        'gene therapy product candidates that are in '
                        'preclinical development for rare inborn errors of '
                        'metabolism, including SEL-302, a therapy program for '
                        'the treatment methylmalonic academia; and SEL-313, a '
                        'product candidate to treat ornithine transcarbamylase '
                        'deficiency. Selecta Biosciences, Inc. has license and '
                        'collaboration agreements with Spark Therapeutics, '
                        'Massachusetts Institute of Technology, Shenyang '
                        'Sunshine Pharmaceutical Co., Ltd., and BIND '
                        'Therapeutics, Inc.; and a strategic partnership with '
                        'Asklepios BioPharmaceutical, Inc. for the '
                        'development, manufacture, and commercialization of '
                        'targeted therapeutics for adeno-associated virus gene '
                        'therapies in the areas of high medical need. The '
                        'company was founded in 2007 and is headquartered in '
                        'Watertown, Massachusetts.',
 'longName': 'Selecta Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 219599136,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_53339386',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -62896000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.57,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617-923-1400',
 'previousClose': 2.61,
 'priceHint': 4,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 32.938225,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 2.59,
 'regularMarketDayLow': 2.47,
 'regularMarketOpen': 2.57,
 'regularMarketPreviousClose': 2.61,
 'regularMarketPrice': 2.57,
 'regularMarketVolume': 822580,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 87489696,
 'sharesPercentSharesOut': 0.1177,
 'sharesShort': 10300107,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6329320,
 'shortName': 'Selecta Biosciences, Inc.',
 'shortPercentOfFloat': 0.1433,
 'shortRatio': 2.16,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'SELB',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.055,
 'twoHundredDayAverage': 3.0789568,
 'volume': 822580,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://selectabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02472'}